Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Current Assets (2020 - 2025)

Historic Current Assets for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $52.4 million.

  • Mereo BioPharma's Current Assets fell 3956.97% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year decrease of 3956.97%. This contributed to the annual value of $74.8 million for FY2024, which is 1725.69% up from last year.
  • Latest data reveals that Mereo BioPharma reported Current Assets of $52.4 million as of Q3 2025, which was down 3956.97% from $61.4 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year Current Assets high stood at $168.2 million for Q2 2021, and its period low was $52.4 million during Q3 2025.
  • For the 5-year period, Mereo BioPharma's Current Assets averaged around $86.1 million, with its median value being $75.0 million (2022).
  • As far as peak fluctuations go, Mereo BioPharma's Current Assets skyrocketed by 24110.21% in 2021, and later crashed by 4383.61% in 2022.
  • Quarter analysis of 5 years shows Mereo BioPharma's Current Assets stood at $133.9 million in 2021, then crashed by 43.84% to $75.2 million in 2022, then dropped by 15.21% to $63.8 million in 2023, then rose by 17.26% to $74.8 million in 2024, then fell by 29.9% to $52.4 million in 2025.
  • Its Current Assets was $52.4 million in Q3 2025, compared to $61.4 million in Q2 2025 and $66.9 million in Q1 2025.